Which has higher earnings and valuation, HELP or CVAC?

CureVac has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is HELP or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Cybin's net margin of 0.00%. CureVac's return on equity of -23.03% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% CureVac 199.92% -23.03% -19.09%

Is SPRY or HELP more profitable?

Cybin has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Cybin's return on equity of -59.98% beat ARS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals -200.00% -153.61% -60.85% Cybin N/A -59.98% -50.80%

Does the media refer more to SPRY or HELP?

In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 1 articles in the media. Cybin's average media sentiment score of 0.00 beat ARS Pharmaceuticals' score of -0.38 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, HELP or ORIC?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A

Is HELP or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% Oric Pharmaceuticals N/A -35.33% -33.31%

Does the media prefer HELP or ORIC?

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Cybin. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 1 mentions for Cybin. Cybin's average media sentiment score of 0.00 equaled Oric Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is HELP or PHAR more profitable?

Pharming Group has a net margin of 3.30% compared to Cybin's net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% Pharming Group 3.30% 4.64% 2.55%

Does the media refer more to HELP or PHAR?

In the previous week, Pharming Group had 3 more articles in the media than Cybin. MarketBeat recorded 4 mentions for Pharming Group and 1 mentions for Cybin. Pharming Group's average media sentiment score of 0.64 beat Cybin's score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, HELP or JBIO?

Jade Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A Jade Biosciences N/A N/A -$127.41M -$2.02 N/A

Is HELP or JBIO more profitable?

Jade Biosciences' return on equity of -51.34% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% Jade Biosciences N/A -51.34% -47.32%

Does the media refer more to HELP or JBIO?

In the previous week, Jade Biosciences had 22 more articles in the media than Cybin. MarketBeat recorded 23 mentions for Jade Biosciences and 1 mentions for Cybin. Jade Biosciences' average media sentiment score of 0.43 beat Cybin's score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jade Biosciences 8 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Cybin (HELP) Competitors

$4.15 -0.28 (-6.32%)

Closing price 04:00 PM Eastern

Extended Trading

$4.10 -0.05 (-1.20%)

As of 07:54 PM Eastern

Compare

HELP vs. CVAC, SPRY, ORIC, PHAR, and JBIO

Should you buy Cybin stock or one of its competitors? MarketBeat compares Cybin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cybin include CureVac (CVAC), ARS Pharmaceuticals (SPRY), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry.

How does Cybin compare to CureVac?

Cybin (NASDAQ:HELP) and CureVac (NASDAQ:CVAC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

In the previous week, Cybin had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Cybin and 0 mentions for CureVac. Cybin's average media sentiment score of 0.00 equaled CureVac'saverage media sentiment score.

Company	Overall Sentiment
Cybin	Neutral
CureVac	Neutral

Cybin has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

17.9% of Cybin shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CureVac has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Cybin presently has a consensus price target of $58.75, indicating a potential upside of 1,315.66%. CureVac has a consensus price target of $5.25, indicating a potential upside of 12.66%. Given Cybin's stronger consensus rating and higher possible upside, equities analysts plainly believe Cybin is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

CureVac has a net margin of 199.92% compared to Cybin's net margin of 0.00%. CureVac's return on equity of -23.03% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
CureVac	199.92%	-23.03%	-19.09%

Summary

CureVac beats Cybin on 8 of the 14 factors compared between the two stocks.

How does Cybin compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

ARS Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Cybin has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Cybin has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	10.09	-$171.30M	-$2.01	N/A
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cybin has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Cybin's return on equity of -59.98% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Cybin	N/A	-59.98%	-50.80%

In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 1 articles in the media. Cybin's average media sentiment score of 0.00 beat ARS Pharmaceuticals' score of -0.38 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals currently has a consensus price target of $28.60, suggesting a potential upside of 234.11%. Cybin has a consensus price target of $58.75, suggesting a potential upside of 1,315.66%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Cybin beats ARS Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Cybin compare to Oric Pharmaceuticals?

Cybin (NASDAQ:HELP) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Cybin has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Cybin currently has a consensus price target of $58.75, indicating a potential upside of 1,315.66%. Oric Pharmaceuticals has a consensus price target of $19.36, indicating a potential upside of 158.18%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cybin is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

17.9% of Cybin shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Cybin. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 1 mentions for Cybin. Cybin's average media sentiment score of 0.00 equaled Oric Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals' return on equity of -35.33% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Summary

Oric Pharmaceuticals beats Cybin on 7 of the 12 factors compared between the two stocks.

How does Cybin compare to Pharming Group?

Cybin (NASDAQ:HELP) and Pharming Group (NASDAQ:PHAR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

17.9% of Cybin shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Pharming Group	$376.13M	2.37	$2.85M	$0.16	78.84

Cybin presently has a consensus price target of $58.75, indicating a potential upside of 1,315.66%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 203.87%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has a net margin of 3.30% compared to Cybin's net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Pharming Group	3.30%	4.64%	2.55%

Cybin has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

In the previous week, Pharming Group had 3 more articles in the media than Cybin. MarketBeat recorded 4 mentions for Pharming Group and 1 mentions for Cybin. Pharming Group's average media sentiment score of 0.64 beat Cybin's score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pharming Group beats Cybin on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to Jade Biosciences?

Cybin (NASDAQ:HELP) and Jade Biosciences (NASDAQ:JBIO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Jade Biosciences' return on equity of -51.34% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Jade Biosciences	N/A	-51.34%	-47.32%

17.9% of Cybin shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 23.1% of Jade Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Jade Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Cybin has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market.

In the previous week, Jade Biosciences had 22 more articles in the media than Cybin. MarketBeat recorded 23 mentions for Jade Biosciences and 1 mentions for Cybin. Jade Biosciences' average media sentiment score of 0.43 beat Cybin's score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jade Biosciences	8 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cybin currently has a consensus target price of $58.75, suggesting a potential upside of 1,315.66%. Jade Biosciences has a consensus target price of $47.43, suggesting a potential upside of 179.98%. Given Cybin's stronger consensus rating and higher probable upside, research analysts clearly believe Cybin is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Jade Biosciences beats Cybin on 8 of the 13 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$214.27M	$2.93B	$4.24B	$11.97B
Dividend Yield	N/A	15.17%	7.93%	5.32%
P/E Ratio	-0.98	13.61	21.75	23.66
Price / Sales	N/A	3,152.35	213.09	86.29
Price / Cash	N/A	28.12	53.68	55.53
Price / Book	0.53	5.91	27.92	6.39
Net Income	-$81.31M	-$40.08M	$109.80M	$337.36M
7 Day Performance	-8.79%	-1.93%	-3.42%	-3.07%
1 Month Performance	-20.50%	0.04%	1.21%	0.37%
1 Year Performance	N/A	15.61%	12.95%	27.87%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	2.3129 of 5 stars	$4.15 -6.3%	$58.75 +1,315.7%	N/A	$228.73M	N/A	N/A	50
CVAC CureVac	N/A	$4.66 flat	$5.25 +12.7%	N/A	$960.17M	$70.74M	6.47	880
SPRY ARS Pharmaceuticals	2.4554 of 5 stars	$8.90 -5.6%	$28.60 +221.3%	-34.4%	$936.43M	$84.28M	N/A	90
ORIC Oric Pharmaceuticals	2.3876 of 5 stars	$7.62 -15.1%	$19.36 +154.1%	-11.7%	$929.59M	N/A	N/A	80	Gap Down High Trading Volume
PHAR Pharming Group	4.011 of 5 stars	$12.28 -6.3%	$38.33 +212.2%	+2.5%	$925.19M	$376.13M	76.75	280	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors

HELP vs. CVAC, SPRY, ORIC, PHAR, and JBIO

How does Cybin compare to CureVac?

Summary

How does Cybin compare to ARS Pharmaceuticals?

Summary

How does Cybin compare to Oric Pharmaceuticals?

Summary

How does Cybin compare to Pharming Group?

Summary

How does Cybin compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cybin (HELP) Competitors

HELP vs. CVAC, SPRY, ORIC, PHAR, and JBIO

How does Cybin compare to CureVac?

Does the media prefer HELP or CVAC?

Which has more volatility and risk, HELP or CVAC?

Do institutionals and insiders have more ownership in HELP or CVAC?

Which has higher earnings and valuation, HELP or CVAC?

Do analysts recommend HELP or CVAC?

Is HELP or CVAC more profitable?

Summary

How does Cybin compare to ARS Pharmaceuticals?

Which has more risk & volatility, SPRY or HELP?

Which has higher earnings and valuation, SPRY or HELP?

Do insiders & institutionals hold more shares of SPRY or HELP?

Is SPRY or HELP more profitable?

Does the media refer more to SPRY or HELP?

Do analysts prefer SPRY or HELP?

Summary

How does Cybin compare to Oric Pharmaceuticals?

Which has more volatility and risk, HELP or ORIC?

Do analysts rate HELP or ORIC?

Do institutionals & insiders believe in HELP or ORIC?

Does the media prefer HELP or ORIC?

Is HELP or ORIC more profitable?

Which has preferable earnings and valuation, HELP or ORIC?

Summary

How does Cybin compare to Pharming Group?

Do institutionals & insiders believe in HELP or PHAR?

Which has preferable valuation and earnings, HELP or PHAR?

Do analysts rate HELP or PHAR?

Is HELP or PHAR more profitable?

Which has more risk and volatility, HELP or PHAR?

Does the media refer more to HELP or PHAR?

Summary

How does Cybin compare to Jade Biosciences?

Is HELP or JBIO more profitable?

Do institutionals and insiders hold more shares of HELP or JBIO?

Which has stronger valuation & earnings, HELP or JBIO?

Which has more risk and volatility, HELP or JBIO?

Does the media refer more to HELP or JBIO?

Do analysts recommend HELP or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools